CN112480055B - 一种橙皮素衍生物及其合成方法与用途 - Google Patents
一种橙皮素衍生物及其合成方法与用途 Download PDFInfo
- Publication number
- CN112480055B CN112480055B CN202011441745.3A CN202011441745A CN112480055B CN 112480055 B CN112480055 B CN 112480055B CN 202011441745 A CN202011441745 A CN 202011441745A CN 112480055 B CN112480055 B CN 112480055B
- Authority
- CN
- China
- Prior art keywords
- hesperetin
- derivative
- present
- free radical
- bromoacetanilide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002388 hesperetin derivatives Chemical class 0.000 title claims abstract description 33
- 238000010189 synthetic method Methods 0.000 title 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 32
- 229960001587 hesperetin Drugs 0.000 claims abstract description 27
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 26
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 26
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940123457 Free radical scavenger Drugs 0.000 claims abstract description 7
- 239000002516 radical scavenger Substances 0.000 claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 5
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 5
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 5
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 5
- 229940025878 hesperidin Drugs 0.000 claims description 5
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 5
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- FWLGGSWAIHNLLW-UHFFFAOYSA-N n-bromo-n-phenylacetamide Chemical compound CC(=O)N(Br)C1=CC=CC=C1 FWLGGSWAIHNLLW-UHFFFAOYSA-N 0.000 claims 3
- 238000001816 cooling Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 22
- 150000003254 radicals Chemical class 0.000 abstract description 15
- 230000002000 scavenging effect Effects 0.000 abstract description 12
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 150000001408 amides Chemical group 0.000 abstract description 5
- 230000007760 free radical scavenging Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000003712 anti-aging effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract description 3
- 238000012512 characterization method Methods 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- -1 bisamide compound Chemical class 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 11
- DCPLOIFDMMEBQZ-UHFFFAOYSA-N 2-bromo-n-phenylacetamide Chemical compound BrCC(=O)NC1=CC=CC=C1 DCPLOIFDMMEBQZ-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004896 high resolution mass spectrometry Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical class NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000675108 Citrus tangerina Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical class OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- PFANGGLDSSGAFJ-UHFFFAOYSA-N [NH4+].[NH4+].[N+](=[N-])(C1SC2=C(N1CC)C=CC(=C2)S(=O)(=O)[O-])C2SC1=C(N2CC)C=CC(=C1)S(=O)(=O)[O-] Chemical compound [NH4+].[NH4+].[N+](=[N-])(C1SC2=C(N1CC)C=CC(=C2)S(=O)(=O)[O-])C2SC1=C(N2CC)C=CC(=C1)S(=O)(=O)[O-] PFANGGLDSSGAFJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 102000009854 cortexin Human genes 0.000 description 1
- 108010034906 cortexin Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种橙皮素衍生物,以及它的合成方法与它的用途。本发明所述的橙皮素衍生物,具有如图所示的化学结构式。本发明以二氢黄酮橙皮素为先导化合物,通过对其7‑OH进行结构修饰导入酰胺结构,设计合成了所述的橙皮素衍生物,利用核磁波谱技术和高分辨质谱对其结构进行了表征,并对目标产物进行了体外清除自由基活性测试。实验结果表明目标化合物对所测试自由基具有抑制活性,且抑制作用强于橙皮素。因此,本发明所述的橙皮素衍生物可用于制备自由基清除剂,并进一步用于制备与清除自由基相关的抗氧化、抗炎、抗衰老、降低血脂或抗肿瘤的药物。
Description
技术领域
本发明涉及一种橙皮素衍生物,以及它的合成方法与它的用途。
背景技术
生物体内过量自由基的存在可能导致DNA断裂以及脂质过氧化而引发细胞凋亡,诱发炎症、动脉粥样硬化、癌症等多种疾病,凡能干扰自由基链反应中链引发和链增长过程、清除自由基的化合物统称为抗氧化剂或自由基捕获剂,按照来源可分为人工合成类和天然类,人工合成抗氧化剂主要有含羟基类、含N-H键类、含S、Se、Te类,天然抗氧化剂主要有维生素类、黄酮类、茶多酚和白藜芦醇等。
橙皮素(Hesperetin)是一种天然二氢黄酮类化合物,广泛存在于水果、花卉等植物源物质中,具有抗氧化、抗炎、抗衰老、降低血脂及抗肿瘤等多种生物学活性。由橙皮素所得衍生物亦具有多方面的药理作用,已报道化合物HDND-XIV对佐剂性关节炎大鼠成纤维滑膜细胞炎症有明显影响;已发现化合物MTBH能显著抑制脂多糖刺激RAW264.7细胞分泌的白介素-6和肿瘤坏死因子-α,同时对转化生长因子-β诱导的HSC-T6细胞增殖活化有明显的抑制作用,表明其对肝纤维化有保护和治疗作用。
氮氢键类化合物可以直接与自由基作用,关于氨基衍生物的抗氧化活性也时有报道,已报道章鱼胺衍生物OA08的抗氧化活性明显高于章鱼胺的前体化合物酪胺;已发现双酰胺化合物DA8具有较强的抑制过氧自由基引发的DNA氧化反应的能力。
发明内容
本发明的第一个目的在于提供一种橙皮素衍生物。
本发明所述的橙皮素衍生物,具有如下所示的化学结构式:
优选地,本发明所述的橙皮素衍生物的化学结构式中,R=H。
本发明的第二个目的在于提供所述的橙皮素衍生物的合成方法。
本发明所述的橙皮素衍生物的合成方式包括以下步骤:以苯胺、溴乙酰氯和橙皮素为起始原料,在橙皮素分子中导入酰胺结构,合成所述的橙皮素衍生物,利用核磁波谱技术和高分辨质谱对其结构进行表征。
优选地,本发明所述的橙皮素衍生物的合成方式包括以下步骤:
A.橙皮素的制备:从中药陈皮中提取分离得到橙皮苷,经酸水解得到橙皮素;
B.N-溴乙酰基苯胺的合成:将苯胺溶于二氯甲烷中,再加入碳酸钾,常温下搅拌,慢慢滴加溴乙酰氯,回流反应,冷却,过滤,滤液浓缩后直接用无水乙醇/水重结晶,干燥,得到N-溴乙酰基苯胺;
C.将摩尔比例为1:1:1的橙皮素、N-溴乙酰基苯胺和NaOH溶于无水乙醇中,回流反应,TLC跟踪至反应完成,冷却,过滤,水洗,干燥后得到粗产品;(目标化合物1)。合成路线如图1所示。
D.将粗产品用无水乙醇进行重结晶,得到纯品即所述的橙皮素衍生物。
本发明的第二个目的在于提供所述的橙皮素衍生物的用途。
本发明所述的橙皮素衍生物可用于制备自由基清除剂。
本发明所述的橙皮素衍生物可用于制备抗氧化、抗炎、抗衰老、降低血脂或抗肿瘤的药物。
本发明以二氢黄酮橙皮素为先导化合物,通过对其7-OH进行结构修饰导入酰胺结构,设计合成了所述的橙皮素衍生物,利用核磁波谱技术和高分辨质谱对其结构进行了表征,并以2,2-二苯基-1-苦味酰基(DPPH)自由基、2,2'-联氨-双(3-乙基苯并噻唑啉-6-磺酸)二胺盐(ABTS)自由基和羟基自由基(·OH)为模型对目标产物进行了体外清除自由基活性测试。实验结果表明目标化合物对所测试自由基具有抑制活性,且抑制作用强于橙皮素。因此,本发明所述的橙皮素衍生物可用于制备自由基清除剂,并进一步用于制备与清除自由基相关的抗氧化、抗炎、抗衰老、降低血脂或抗肿瘤的药物。
附图说明
图1为本发明所述的橙皮素衍生物的合成路线。
图2为目标化合物1即本发明所述的橙皮素衍生物的核磁共振氢谱(1H NMR)。
图3为目标化合物1即本发明所述的橙皮素衍生物的核磁共振碳谱(13C NMR)。
图4为目标化合物1即本发明所述的橙皮素衍生物的高分辨质谱图(HR-MS)。
图5为目标化合物1即本发明所述的橙皮素衍生物的结构。
图6显示目标化合物1即本发明所述的橙皮素衍生物对自由基的清除作用。
具体实施方式
实施例一:本发明所述的橙皮素衍生物的合成
1.仪器与试剂
RE-52AA旋转蒸发器(上海亚荣生化仪器厂);SHZ-DⅢ循环水真空泵(郑州市亚荣仪器有限公司);WD-9403C紫外仪(北京市六一仪器厂);DF-101S集热式恒温加热磁力搅拌器(巩义市英峪予华仪器厂制造);JA2603B电子分析天平、YP502N电子分析天平(上海精密科学仪器有限公司);722S可见分光光度计(上海精密科学仪器有限公司);UV2550型紫外可见分光光度计(日本岛津);TDL-408低速台式离心机(上海安亭科学仪器厂);X-4B型显微熔点测定仪(上海申光仪表仪器有限公司);Avance AV 500MHz型超导核磁共振仪(TMS作内标);Waters UPLC-SQD单四极杆液质联用仪。
溴乙酰氯、苯胺、碳酸钾、氢氧化钠、磷酸二氢钠(NaH2PO4)、铁氰化钾(K3Fe(CN)6)、磷酸氢二钠(Na2HPO4)、三氯乙酸(TCA)、三氯化铁(FeCl3)、硫酸亚铁(FeSO4)、30%双氧水(H2O2)、水杨酸(Salicylic acid,SA)、1,1-二苯基-2-三硝基苯肼(DPPH)、氯化钠(NaCl)、氯化钾(KCl)、磷酸氢二钾(K2HPO4)、磷酸二氢钾(KH2PO4)、过硫酸钾(K2S2O8)、2,2’-联氮-二(3-乙基-苯并噻唑-6-磺酸)二铵盐(ABTS)以及无水乙醇、丙酮、冰醋酸、二甲亚砜、二氯甲烷等试剂均为国产分析纯。
2.目标化合物的合成
2.1橙皮素的制备
参考文献[单杨,李高阳,汪秋安,等.橙皮苷半合成5种生物活性黄酮类化合物[J].有机化学,2008,38(06):1024-1028.]和文献[朱思明,于淑娟,扶雄.橙皮苷提取方法的研究[J].食品研究与开发,2009,30(07):17-20.]的制备方法:从中药陈皮中提取分离得到橙皮苷,经酸水解得到橙皮素。
2.2N-溴乙酰基苯胺的合成
参考文献[刘汉文,邹亚丽,唐子龙.氯乙酰芳胺类化合物的合成及表征[J].湖南科技大学学报(自然科学版),2013,28(03):88-91.]的制备方法:10mmol苯胺溶于60mL二氯甲烷中,再加入25mmol碳酸钾,常温下磁力搅拌30分钟,再慢慢滴加11mmol溴乙酰氯,回流反应4小时,冷却,过滤,滤液浓缩后直接用无水乙醇/水重结晶,干燥,得到N-溴乙酰基苯胺。
2.3含酰胺结构的橙皮素衍生物的合成
将1mmol橙皮素、1mmol N-溴乙酰基苯胺和1mmol NaOH溶于10mL无水乙醇中。回流反应,TLC跟踪至反应完成。冷却,过滤,水洗,干燥后得到粗产品。将粗产品用无水乙醇进行重结晶得到纯品3’,7-O-二(苯胺酰甲基)-橙皮素(目标化合物1)。合成路线如图1所示。
3.目标化合物的结构鉴定
观察目标化合物的形状、颜色,称重并计算产率,测定熔点,用薄层层析(TLC)检测其纯度并计算比移值(Rf),测试溶解性,测定其核磁共振氢谱(1H-NMR)、碳谱(13C-NMR))及高分辨质谱(HR-MS)。
4.目标化合物体外清除自由基活性
将橙皮素和其衍生物先用少量二甲基亚砜溶解,再用无水乙醇定容,分别配成浓度为0.125、0.25、0.50、1.0、2.0mg/mL的溶液,进行清除自由基活性测定。对羟基自由基(·OH)的清除作用参考本领域的文献方法进行,对DPPH自由基的清除作用参考本领域的文献方法进行,对ABTS自由基的清除活性参考本领域的文献进行。
实施例二:本发明所述的橙皮素衍生物的合成结果与分析
1.目标化合物的理化性质
目标化合物1为米白色固体,产率为56.40%,熔点为211~213℃,能溶解于丙酮、氯仿和二甲基亚砜,微溶于乙醇。薄层层析比移值为0.61(展开剂为石油醚:乙酸乙酯=2:1)。
2.目标化合物的结构鉴定
采用仪器分析方法鉴定目标化合物的结构,核磁共振氢谱见图2,核磁共振碳谱见图3,高分辨质谱见图4。
从图2可以看出:1H NMR(500MHz,DMSO-d6)δppm:2.85(d,J=17.0Hz,1H,3-Hcis),3.09(dd,J=13.0,17.0Hz,1H,3-H trans),3.97(s,3H,4′-OCH3),4.60(s,2H,OCH2),4.69(s,2H,OCH2),5.39(d,J=11.5Hz,1H,2-H),6.15(d,J=9.0Hz,2H,Ph-H),6.99(d,J=8.5Hz,1H,6′-H),7.10~7.18(m,3H,Ph-H),7.26(s,1H,Ph-H),7.36(t,J=8.0Hz,4H,Ph-H),7.58(t,J=8.5Hz,4H,Ph-H),8.11(s,1H,NH),8.85(s,1H,NH),11.98(s,1H,5-OH)。
从图3可以看出:13C NMR(125MHz,DMSO-d6)δppm:43.11(C-3),56.11(OCH3),67.30(OCH2),70.39(OCH2),78.68(C-2),94.66(C-8),96.12(C-6),104.01(C-9),112.14(C-5′),114.65(C-2′),119.89(C-6′),120.17(2C-Ph),121.45(2C-Ph),124.74(2C-Ph),125.08(1C-Ph),129.09(2C-Ph),129.12(1C-Ph),131.13(C-1′),136.55(1C-Ph),137.07(1C-Ph),147.43(C-3′),150.35(C-4′),162.85(C-10),164.22(C-5),164.65(C-7),164.86(CONH),166.50(CONH),195.81(C-4)。
从图4可以看出:HR-MS C32H28N2O8(m/z,%):591.1738([M+Na]+,100%)。由目标化合物1的核磁共振氢谱、碳谱和高分辨质谱分析可知,橙皮素和N-溴乙酰基苯胺在碱性条件下发生双缩合反应,所得化合物的结构如图5所示。
3.目标化合物清除自由基结果与分析
体外清除自由基的模型实验较多,本发明根据实验室条件,以先导化合物橙皮素为对照,对其衍生物进行了不同浓度下清除羟基自由基、DPPH自由基和ABTS自由基的对比实验,实验结果见图6。
由上述结果可以看出,在三种不同的体外清除自由基模型中,化合物1的清除作用均强于原料橙皮素,且与浓度呈相关性,在浓度为2.0mg/mL时对不同自由基的清除大小为:DPPH自由基>ABTS自由基>羟自由基。
结论
本发明以苯胺和溴乙酰氯为原料,通过乙酰化反应得到N-溴乙酰基苯胺,将其与橙皮素在碱性条件下缩合得到相应的含酰胺结构的橙皮素衍生物。对合成的化合物进行高分辨质谱(HR-MS)和核磁共振氢谱(1H-NMR)、核磁共振碳谱(13C-NMR)图谱分析,鉴定其结构,并以橙皮素做对照,对其进行清除自由基能力测定。清除DPPH自由基、羟自由基(·OH)和ABTS自由基检测结果表明该衍生物有一定的清除自由基作用,且目标化合物1在不同的清除自由基模型中,作用均强于先导化合物橙皮素,有望用于制备自由基清除剂,进一步进行体内实验研究。
Claims (4)
2.如权利要求1所述的橙皮素衍生物的合成方式,其特征在于,包括以下步骤:
A.橙皮素的制备:从中药陈皮中提取分离得到橙皮苷,经酸水解得到橙皮素;
B.N-溴乙酰基苯胺的合成:将苯胺溶于二氯甲烷中,再加入碳酸钾,常温下搅拌,慢慢滴加溴乙酰氯,回流反应,冷却,过滤,滤液浓缩后直接用无水乙醇/水重结晶,干燥,得到N-溴乙酰基苯胺;
C.将摩尔比例为1:1:1的橙皮素、N-溴乙酰基苯胺和NaOH溶于无水乙醇中,回流反应,TLC跟踪至反应完成,冷却,过滤,水洗,干燥后得到粗产品;
D.将粗产品用无水乙醇进行重结晶,得到纯品即所述的橙皮素衍生物。
3.如权利要求1所述的橙皮素衍生物用于制备自由基清除剂的用途。
4.如权利要求3所述的用途,其特征在于:所述自由基清除剂用于制备抗氧化、抗炎、抗衰老、降低血脂的药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011441745.3A CN112480055B (zh) | 2020-12-11 | 2020-12-11 | 一种橙皮素衍生物及其合成方法与用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011441745.3A CN112480055B (zh) | 2020-12-11 | 2020-12-11 | 一种橙皮素衍生物及其合成方法与用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112480055A CN112480055A (zh) | 2021-03-12 |
| CN112480055B true CN112480055B (zh) | 2022-10-21 |
Family
ID=74940103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011441745.3A Active CN112480055B (zh) | 2020-12-11 | 2020-12-11 | 一种橙皮素衍生物及其合成方法与用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112480055B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113045527B (zh) * | 2021-03-22 | 2022-11-08 | 广东省科学院动物研究所 | 二氢色原酮衍生物及其合成方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9603325D0 (en) * | 1996-02-16 | 1996-04-17 | Imperial College | A compound |
| DE10244282A1 (de) * | 2002-09-23 | 2004-04-01 | Merck Patent Gmbh | Zubereitung mit antioxidanten Eigenschaften |
| CN101774993A (zh) * | 2010-02-05 | 2010-07-14 | 江苏工业学院 | 白杨素含氮衍生物及其制备方法和用途 |
| CN101891730B (zh) * | 2010-07-30 | 2013-01-02 | 西南大学 | 7-烷氧基甲基橙皮素的合成及其制药用途 |
-
2020
- 2020-12-11 CN CN202011441745.3A patent/CN112480055B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112480055A (zh) | 2021-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tishler et al. | The reaction between o-aminoazo compounds and barbituric acid. A new synthesis of riboflavin | |
| CN101003528A (zh) | 新对映贝壳杉烯类二萜化合物及其衍生物、其制备方法和用途 | |
| AU2008201553A1 (en) | Composition for treating cancer cells and synthetic method for the same | |
| CN101717411B (zh) | 去甲基斑蝥素衍生物磷酸二钠盐及其合成方法与用途 | |
| CN110128382B (zh) | 一种水黄皮籽素的制备方法和应用 | |
| CN112480055B (zh) | 一种橙皮素衍生物及其合成方法与用途 | |
| CN113444084A (zh) | 一类抗肿瘤化合物及其制备与用途 | |
| CN113045399B (zh) | 查尔酮衍生物及其用途 | |
| CN110128343A (zh) | 一种酰肼类化合物 | |
| JP7123417B2 (ja) | 抗不安重水素化合物及びその医薬的用途 | |
| Moustafa et al. | A coumarin with an unusual structure from Cuphea ignea, its cytotoxicity and antioxidant activities | |
| Wang et al. | Garcinol and its analogues: Synthesis, cytotoxic activity and mechanistic investigation | |
| CN114656438A (zh) | 一种5,7-二羟基-2,2-二甲基-6-乙酰基-色满及其合成方法和应用 | |
| CN119735591A (zh) | 负载荧光基团的含硒小分子及其制备方法和应用 | |
| CN102898502B (zh) | 香豆素衍生物及其制备方法和应用 | |
| CN101575343B (zh) | 一种去甲斑蝥素酯化衍生物及其制法 | |
| Liu et al. | Design, synthesis, and anti-tumor activity of (2-O-alkyloxime-3-phenyl)-propionyl-1-O-acetylbritannilactone esters | |
| CN101591316A (zh) | 高异黄酮、二氢高异黄酮、高异黄烷类衍生物及其用途 | |
| CN113149942A (zh) | 一种洛克米兰醇酚羟基衍生物、其制备方法和应用 | |
| Wang et al. | Synthesis, structure and tyrosinase inhibition of natural phenols derivatives | |
| Mehta et al. | Synthesis and in-vitro antioxidant activity of some new 2, 5-disubstituted-1, 3, 4-oxadiazoles containing furan moiety | |
| Siyi et al. | A flavone-based long-wavelength fluorescent probe to detect biothiols in vitro and in vivo | |
| US20250042838A1 (en) | Process for the synthesis and purification of cannabinoic acids and acylated derivatives thereof | |
| Woydziak et al. | Efficient and scalable synthesis of 4-carboxy-pennsylvania green methyl ester: a hydrophobic building block for fluorescent molecular probes | |
| CN113321634A (zh) | 一种长链伯酰胺白杨素衍生物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230605 Address after: 526060 Room A16, Cultural Creative Park, University Science Park, Zhaoqing University, Duanzhou District, Zhaoqing, Guangdong Province Patentee after: Guangdong Green Wind Environmental Protection Technology Co.,Ltd. Address before: 526061 Guangdong Province, Zhaoqing city Duanzhou District Donggang Zhaoqing University Patentee before: ZHAOQING University |
|
| TR01 | Transfer of patent right |